Isoleucine

Evidence Level: L5

Predicted Indications: 1

Isoleucine

Pharmacist Assessment Report

Isoleucine: From Maple Syrup Urine Disease Dietary Management to Gastroparesis

One-Sentence Summary

Isoleucine is an essential branched-chain amino acid. In Australia it is marketed in single-ingredient and amino acid formula products used in the dietary management of maple syrup urine disease (MSUD). The TxGNN model predicts it may be effective for gastroparesis, but there are currently no clinical trials and no publications supporting this direction.

Quick Overview

Item	Content
Original Indication	Not stated in the registration data; the product names (MSUD amino5, MSUD Easy Tablet, MSUD Anamix Junior, MSUD Explore5) suggest use in MSUD dietary management
Predicted New Indication	Gastroparesis
TxGNN Prediction Score	0.9932
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (5 of 5 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	5 (valid: 5)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, isoleucine is a branched-chain amino acid used in nutrition and metabolic formulas. Its role in the original setting appears to be nutritional and metabolic, and any mechanistic link to gastroparesis remains speculative.

Gastroparesis involves delayed gastric emptying caused by impaired motility (for example, diabetic or idiopathic causes). The data compiled for this report do not establish a pathway from isoleucine to this condition. One speculative route is through nutrient and amino acid sensing that may influence gastric emptying, but nothing in the data supports it.

The high TxGNN score (0.9932) is a computational prediction only. It should be treated as a hypothesis for investigation, not as evidence of efficacy.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 9134R	Isoleucine 50	Oral powder sachets, 4 g (50 mg isoleucine), 30	Not stated in the data
ARTG 10161T	MSUD amino5	Oral powder sachets, 6 g, 30	Not stated in the data
ARTG 12014H	MSUD Easy Tablet	Tablets, 0.91 g protein, 462	Not stated in the data
ARTG 10259Y	MSUD Anamix Junior	Oral powder sachets, 36 g, 30	Not stated in the data
ARTG 14118C	MSUD Explore5	Oral powder sachets, 12.5 g, 30	Not stated in the data

All five entries are valid, single-ingredient products for oral use.

Safety Considerations

Knowledge-graph contraindication signals (from drug-disease relationships in the TxGNN knowledge graph, not from label text): kidney disease, chronic kidney disease, chronic renal failure, end-stage renal failure, nephrolithiasis, nephrocalcinosis, acute urate nephropathy, hypercalcaemia (including humoral hypercalcaemia of malignancy), sarcoidosis, phosphorus metabolism disorders, heart and cardiovascular disease, ventricular fibrillation, digitalis poisoning, phenylketonuria and other disorders of phenylalanine metabolism, pyoureter, and SLC26A1-related nephrolithiasis susceptibility. These should be verified against official product information.

For label warnings, contraindications and drug interactions, please refer to the TGA-approved Product Information (PI) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a model score alone (Evidence Level L5). There are no clinical trials, no literature and no established mechanism. The knowledge graph also flags a number of renal, cardiac and metabolic contraindication signals that have not been assessed.

To proceed, the following is needed:

Mechanism of action data (for example from DrugBank) and a plausible pathway linking isoleucine to gastric motility
A literature and trial registry search (including ANZCTR) for amino acid effects on gastric emptying
Official Product Information warnings and contraindications for the registered products, and review of the knowledge-graph contraindication signals
Confirmation of the approved indications for the ARTG entries
Assessment of route and formulation suitability for gastroparesis
Preclinical or small exploratory studies before any clinical consideration
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.